Citius Pharmaceuticals, Inc. — Director's Dealing 2018

Sep 6, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Citius Pharmaceuticals, Inc. (CTXR)
CIK: 0001506251
Period of Report: 2018-09-04

Reporting Person: Bartushak Jaime (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-09-04	Stock Option (Right to Purchase Common Stock)	$1.62	A	70000	Acquired	2028-09-04	Common Stock (70000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	60353	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Purchase Common Stock)	$3.45	2027-09-15	Common Stock (25000)	25000	Direct
Stock Option (Right to Purchase Common Stock)	$10.50	2026-06-06	Common Stock (48267)	48267	Direct

Footnotes

F1: One-third of the shares of the Company's common stock underlying the grant vest on each of the one-year, two-year and three-year anniversary of the vesting commencement date, September 4, 2018, provided that the Reporting Person provides continuous services to the Company as of each such vesting date.

F2: On September 15, 2017 the Reporting Person was granted a ten-year option to purchase 25,000 shares of common stock at an exercise price of $3.45 per share. The options vest as follows: 8,333 shares vest on September 13, 2018, and then 694 shares per month for the next 24 months.

F3: On July 6, 2016 the Reporting Person was granted a ten-year option to purchase 48,267 shares of common stock at an exercise price of $10.50 per share. The options vest as follows: 16,089 shares vest on July 7, 2017, and then 1,341 shares per month for the next 24 months